

PHARMACOBIOCHEMICAL EVALUATION OF RENOPROTECTIVE AGENTS IN CHRONIC KIDNEY DISEASE

¹Varsha .G, ²Dr.Hari Shankar, ³Dr Mohammad Fakruddin, ⁴Priyanka G, ⁵Dr Umesh Kumar Dixit, ⁶S. Sheeba, ⁷S.T. Gopukumar

¹Pharm D 6th year intern, Department of Pharmacy Practice, Vels Institute of Science, Technology and Advanced Studies, VISTAS, Email Id: varuganesan@gmail.com Orcid Id: 0009-0008-8264-5916

²MBBS MD (Biochemistry), Associate Professor, Department of Biochemistry, Azeezia Institute of Medical Sciences and Research, Kollam, Orcid Id: 0009-0008-0226-4452 Email Id: shan.hariz005@gmail.com

³Assistant Professor, Department of General Medicine, Specialization in Medicine, Al Ameen Medical College, Karnataka, Vijayapura-586108, India, Email Id: mdafakrubm@gmail.com Orcid Id 0000-0002-4508-2906

⁴UG Scholar, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai – 602 105, Tamil Nadu, India. Email: priyankagops2004@gmail.com Orcid Id: 0009-0006-7389-8511

⁵Associate Professor, Department of Biochemistry, Sri Siddhi Vinayak Medical College & Hospital, Sambhal (UP), Email Id: dr.u.k.dixit@gmail.com

⁶Department of Obstetrics and Gynaecology, Sarada Krishna Homoeopathic Medical College, (Affiliated to The Tamil Nadu Dr. M.G.R. Medical University, Chennai), Kulasekharam, Kanyakumari District, Tamil Nadu, India Email Id: sheeba.syduu@gmail.com

⁷Nanobioinformatics Unit, Department of General Surgery, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, Tamilnadu, India Email: gopukumar@live.com Orcid id : https://orcid.org/0000-0001-8160-2414

ABSTRACT

Chronic kidney disease is one of the leading causes of morbidity and mortality in the global world, and progressive loss of kidney function under usual clinical practice. Pharmacological interventions aimed at nephroprotection have become a significant part of disease management, but there are no real-life studies to support the relationship between pharmacological exposure and biochemical renal outcomes. To assess the pharmacobiochemical outcomes of renoprotective agents in patients with chronic kidney disease in a normal clinical setting. The medical records of 60 patients who had chronic kidney disease (35 males and 25 females) were used in a retrospective observational study. Pharmacological therapy data and regularly taken renal and biochemical parameters were already obtained. There were analyzes of changes in serum creatinine, estimated glomerular filtration rate, urea, proteinuria, and other biochemical markers to determine the pattern of renal functioning during treatment. A significant percentage of patients were linked with renal function parameter stabilization with the help of renoprotective therapy. There were small improvements in serum creatinine, and the estimated glomerular filtration rate deterioration was reduced in the follow-up. Positive changes in proteinuria and biochemical stability were recorded and there were no gender variations in response. The results validate the clinical utility of the pharmacobiochemical surveillance to evaluate the practical efficacy of renoprotective agents in chronic kidney disease and highlight the significance of continuous pharmacological treatment.

KEYWORDS: Chronic Kidney Disease, Renoprotective Agents, Pharmacobiochemical Evaluation, Renal Function, Nephrology

1. INTRODUCTION

Chronic kidney disease is a significant worldwide issue in terms of being progressive, high morbidity, and a robust correlation with heart issues. The disease is also associated with permanent loss of nephrons, metabolic imbalance, and a slow deterioration of renal function, which eventually results in end-stage kidney disease unless treated. The pharmacological approach to disease progression and maintenance of the remaining renal activity has taken the centre-stage of the modern nephrology practice. Recent discoveries have changed the therapeutic approach towards symptomatic management of the disease to the reno-protective interventions, which could alter the disease pathway. Among them, sodium glucose cotransporter-2 inhibitors, renin-angiotensin-aldosterone system modulators and non-steroidal mineralocorticoid receptor antagonists have shown significant salutary effects on the kidney in various chronic kidney disease patients.

Randomized large-scale trials have proven the effectiveness of dapagliflozin in slowing the progression and death of kidney disease patients with chronic kidney disease, regardless of whether they have diabetes or not [1]. The DAPA-CKD baseline analysis studies noted a wide representation of patients in the range of estimated glomerular filtration rates, which indicates the relevance of the results to the general population [2]. Follow-up outcome evaluations revealed the same level of positive patient outcomes in patients with or without cardiovascular disease, which validated the therapeutic effects of dapagliflozin in patients other than cardiometabolic risk reduction [3]. The recent age- and sex-stratified analyses also indicated the same renal effect in all demographic subgroups, which proved that pharmacological response was equal [4].

Similar progress in mineralocorticoid receptor antagonism has increased treatment choices. Finer none showed great improvements in renal outcomes in patients with chronic kidney disease and type 2 diabetes, and the efficacy was sustained regardless of the grade of glycaemic control [5]. Its clinical relevance and consistency of renal outcome in clinical practice were also supported by real-life studies of FIDELIO-DKD and FIGARO-DKD [6]. DAPA-CKD mortality-based analyses enhanced the survival advantage of renoprotective treatment in high stages of the disease [7].

The renin-angiotensin-aldosterone system regulation is still core to the management of chronic kidney diseases. Comparison of reviews has revealed the mechanistic diversity of pathway modulators and their various effects on renal hemodynamics, fibrosis, and inflammation [8]. There is still controversy on the use of ongoing RAAS blockade in more chronic kidney disease, especially to weigh the renal advantage against hyperkalemia and the potential onset of a rapid deterioration [9]. The reviewers have also highlighted the growing potential of SGLT2 inhibitors as versatile renoprotective agents in addition to glycaemic regulation [10]. Network meta-analyses and umbrella reviews have also placed into context comparative efficacy and safety of cardio-renoprotective therapies of the different classes of drugs [11].

Investigations have also challenged conventional discontinuation procedures of RAAS inhibitors in late-stage disease. The STOP-ACEi trial compared the renal outcome after the withdrawal of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, which produced significant clinical implications to the disease progression management [12]. Comparisons of the calcium channel blockers and RAAS inhibitors using meta-analyses strengthened the better renoprotective profile of RAAS-based therapy [13]. In more detail, the molecular evidence has revealed, in experimental conditions, the pleiotropic reno- and cardioprotective effects of SGLT2 inhibitors regardless of glucose reduction [14]. Taken altogether, these results have broadened the therapeutic paradigms of diabetic and non-diabetic kidney disease [15]. Although there is strong evidence that promotes the application of renoprotective pharmacotherapy, most of the research is based on controlled clinical trials that have stringent inclusion criteria. Trials of this nature tend to be under-representative of the heterogeneity within the real world in disease stage, comorbid burden and treatment adherence. Moreover, there has been extensive research conducted on clinical endpoints (renal failure and mortality), but reduced research on detailed pharmacobiochemical assessment using regularly monitored renal and metabolic parameters. These boundaries comprehend the manner in which the pharmacological interventions are converted to biochemical stabilization in the normal practice of nephrology.

There are still a number of gaps in the literature. To begin with, there are the restricted retrospective analyses, which help in combining pharmacological exposure with biochemical patterns as they occur in real clinical situations. Second, comparative biochemical reactions between genders and disease stages are not well recorded in non-trial conditions. Third, the actual pharmacobiochemical surveillance data are not used in the actual individualised renoprotective strategies. The key to the translation of clinical trial evidence into practical nephrology care is to address these gaps. This can be addressed by a retrospective pharmacobiochemical analysis to determine the renal stabilization of function with the use of clinical data accessible regularly.

Objectives of the Study

1. To evaluate the pharmacobiochemical effects of renoprotective agents on renal function parameters in patients with chronic kidney disease.
2. To assess associations between pharmacological exposure and biochemical indicators of renal disease stabilization under real-world clinical conditions.

2. METHODOLOGY

2.1 Study Design and Setting

This was a study that employed a retrospective observational design in a tertiary-care clinical environment that dealt with nephrology services. The reviews of medical records during a specific study were conducted in order to measure pharmacobiochemical outcomes following the renoprotective therapy in chronic kidney disease. The design allowed the evaluation of real-life clinical practice without the intervention or change of the management of patients. Extraction of data involved clinical and laboratory parameters, which were routinely recorded when giving normal care. This methodology was used to help test the effects of therapies in the natural clinical setting, as a representation of real nephrology practice. The retrospective study design enabled longitudinal evaluation of biochemical parameters and ensured the ethics of the study by using secondary data. The baseline has been determined as the initial reported visit to the nephrology clinic when renoprotective therapy was documented. Follow-up was associated with the latest clinical examination with measured biochemical data, and the minimum follow-up period was three months.

2.2 Study Population and Sample Characteristics

The study used data from 60 known patients with chronic kidney disease, who were identified by preset eligibility criteria. It included 35 male and 25 female patients, who represented various age groups of adults under nephrology follow-up. Identification of patients was conducted by the hospital's medical record databases based on verified CKD diagnostic codes. Individuals who had been exposed to renoprotective pharmacotherapy and complete biochemical records were used only. Patients who had acute kidney injury, who had a history of renal transplantation or who had incomplete lab data were excluded to maintain analytical consistency. The sample chosen allowed sufficient representation of pharmacobiochemical trends analysis at the CKD stages. Gender distribution also allowed the descriptive comparison

whilst staying focused on renal outcomes and not demographic stratification as per the clinical orientation of nephrology research.

2.3 Pharmacological Exposure and Renoprotective Agents

Cases of pharmacology were obtained through the prescription records as recorded during regular visits to the nephrology clinic. Renoprotective agents were considered standard therapeutic classes used to manage chronic kidney disease, including agents that affect renal hemodynamic and metabolic regulation or inflammatory pathways. The duration of exposure to the drug, the frequency of drug dosage, and patterns of combination therapy were captured. The allocation of treatment indicated clinical judgment in the hands of the physician and not the protocol. This prospective assessment was a representation of true prescribing behavior in nephrology care. Relevant comorbid drugs to the average renal functioning adjustment were also recorded to assist in the interpretation of the context. Correlation with biochemical outcomes between reported follow-up times was reinforced by pharmacological classification. The patients were categorized into mutually exclusive groups of pharmacotherapies according to the primary renoprotective agent recorded at baseline.

2.4 Biochemical and Renal Function Assessment

The assessment was based on the regularly measured parameters of renal function reported in laboratory reports. The main measures were serum creatinine, estimated glomerular filtration rate and blood urea. Additional parameters that were considered secondary were electrolyte profiles and measurements of proteinuria, as available. Measurement of all biochemical values was done at standardized clinical time points based on therapeutic exposure periods. The validity of the laboratory analysis was based on institutional protocols, and the reliability of the measurement was guaranteed. The process of data extraction focused on the temporal consistency to allow comparative assessment based on the follow-up duration. This pharmacobiochemical orientation favoured measurements of renal functional patterns as opposed to solitary labs. The chosen biomarkers were indicators of the current practice in nephrology and diagnostic applicability, which supports the appropriateness of publication in a renal-oriented journal with the focus on diagnostics and disease surveillance. Only a subset of the patients had proteinuria and inflammatory or oxidative stress markers, which were analyzed where longitudinal measurements were recorded.

2.5 Data Collection and Ethical Considerations

The electronic and physical medical records were researched using a structured abstraction format as a method of data collection. Data handling was done through removing patient identifiers to ensure a sense of confidentiality. Access to the data was obtained with the help of the institutional review committee. The research was conducted within the framework of the principles of conducting a retrospective clinical study, such as keeping to a minimum the exposure to risk and ensuring the quality and safety of data storage. Only the authorized personnel could access clinical records, and extract variables were restricted to study objectives. The study did not involve any direct contact with patients. The retrospective approach removed therapeutic interference and retained clinical authenticity. Compliance with ethics enhanced methodological rigor and contributed to the acceptance of the peer-reviewed nephrology literature of peer review in the focus of responsible data utilization.

2.6 Statistical Analysis

The statistical analysis was descriptive and was done with validated analytical programs. The summary of continuous or categorical variables was in terms of mean and standard deviation and frequencies and percentages, respectively. Demographic data, pharmacological exposure and renal and biochemical data were descriptively compared between pre-intervention and post-intervention data. Since the research was retrospective and exploratory, no inferential statistical testing, multivariate adjustment or predictive modelling was conducted. The analysis methodology placed more importance on clinical interpretability of drug-biochemical trends under real-life settings as opposed to hypothesis testing, which is in line with observational nephrology research standards.

3. RESULTS

3.1 Baseline Demographic and Clinical Characteristics

In the research, clinical records of 60 patients with a diagnosis of chronic kidney disease were examined. The treatment group consisted of 35 males and 25 females. The general population was used to denote adult patients who were under regular care in the nephrology unit during the study period. The baseline clinical assessment revealed different degrees of chronic kidney disease, with the majority of the patients having moderate to severe renal impairment during the first evaluation. The prevalent comorbidity cases reported consisted of hypertension and metabolic disorders that were treated together as per the usual clinical practice. The baseline biochemical analysis showed high values of serum creatinine and low values of estimated glomerular filtration rate in the cohort. There was no significant difference in the parameters of the baseline renal functioning based on gender. The demographic sample embraced a representative real-life evaluation of the pharmacobiochemical effects in the management of chronic kidney diseases.

Table 1. Baseline Demographic and Clinical Characteristics of the Study Population (n = 60)

Characteristic	Value
Gender, n (%)	

Male	35 (58.3)
Female	25 (41.7)
Age (years), mean $\pm$ SD	54.6 $\pm$ 11.2
CKD stage at baseline, n (%)	
Stage 3	26 (43.3)
Stage 4	22 (36.7)
Stage 5 (non-dialysis)	12 (20.0)
Comorbid conditions, n (%)	
Hypertension	44 (73.3)
Type 2 diabetes mellitus	32 (53.3)
Dyslipidemia	28 (46.7)
Baseline renal parameters (mean $\pm$ SD)	
Serum creatinine (mg/dL)	2.48 $\pm$ 0.62
Estimated GFR (mL/min/1.73 m ²)	32.6 $\pm$ 8.4
Blood urea (mg/dL)	68.2 $\pm$ 14.5
Gender-based difference in renal parameters	Not statistically significant

3.2 Distribution of Renoprotective Pharmacotherapy

The most commonly used therapeutic class (37%) was angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, in which 22 patients were prescribed them. Sodium-glucose cotransporter was used, and inhibitors were given to 18 patients (30%), as it is increasingly used in the management of chronic kidney diseases. Eight patients (13%) were treated with mineralocorticoid receptor antagonists; mostly patients with more advanced disease or with metabolic indications. The use of two (or more) renoprotective agents in combination therapy was recorded in 12 patients (20%), which suggests an individual approach to therapy, as Figure 1 shows. There was also an equal distribution of pharmacological exposure between the male and female patients, and there was no disproportionate distribution. Such a distribution corresponds to the modern practice of nephrology and represents a quantitative index to explain the effect of later pharmacobiochemical results. The patients were divided into mutually exclusive treatment groups according to the primary treatment regimen recorded during the baseline.




Figure 1. Distribution of Renoprotective Pharmacotherapy

3.3 Changes in Renal Function Parameters

The comparative analysis indicated that there were quantifiable alterations in the parameters of renal function after exposure to pharmacological agents. Serum creatinine levels were reduced with a small margin between baseline (2.48 $\pm$ 0.62mg /dl) and post-follow-up (2.34 $\pm$ 0.58mg /dl) based on Table 2, with 41 patients (68.3% pictorially) showing stabilization or improvement. Estimated glomerular filtration rate exhibited a diminution of deterioration with improvement of 32.6 $\pm$ 8.4 to 34.9 $\pm$ 8.9 mL/min/1.73 m², especially in the patients undergoing sustained renoprotective treatment. The mean blood urea levels reduced to 62.7 $\pm$ 13.9 mg/dL, and the results were more significant in patients with the middle disease stages and a longer length of treatment. There were no statistically significant gender disparities in similar renal functional patterns in male and female patients. In general, these numeric tendencies pointed to maintenance of residual renal activity over renal impairment, which were in accordance with biochemical stabilization

linked with renoprotective therapy within the framework of the real-world clinical setting and in accordance with the modern therapeutic goal of chronic kidney disease management.

Table 2. Changes in Renal Function Parameters Following Renoprotective Therapy (n = 60)

Renal Parameter	Baseline (Mean ± SD)	Follow-up (Mean ± SD)	Change / Interpretation
Serum creatinine (mg/dL)	2.48 ± 0.62	2.34 ± 0.58	Mild reduction/stabilization
Estimated glomerular filtration rate (mL/min/1.73 m ²)	32.6 ± 8.4	34.9 ± 8.9	Slowed decline / slight improvement
Blood urea (mg/dL)	68.2 ± 14.5	62.7 ± 13.9	Moderate reduction
Patients with stable renal function, n (%)	—	41 (68.3%)	Renal function preserved
Gender-based difference	—	—	Not statistically significant

3.4 Biochemical Profile Trends During Follow-Up

Secondary biochemical assessment analysis, as outlined in Table 3, showed positive trends in a number of metabolic and renal-related parameters in follow-up. Mean proteinuria values plummeted at baseline of 1.42, the same way as 1.12 positive and 0.51 g/day, and 36 (60.0) of the patients demonstrated significant proteinuria reduction, which implied a stronger glomerular integrity level. There were no problems with electrolyte parameters during the course of observation; serum sodium was 138.1 and serum potassium was 4.5, which is indicative of stable metabolic control in therapy. The inflammatory markers, such as C-reactive protein, showed a decreasing trend of 6.8 +2.4 to 5.3 +2.1 mg/L in patients with longitudinal data available. Pointers of oxidative stress also exhibited moderate decreases. There was no biochemical degradation due to treatment. In totality, these results demonstrated the clinical value of biochemical monitoring in therapeutic response to renoprotective treatment of chronic kidney disease.

Table 3. Biochemical Profile Trends During Follow-Up in CKD Patients (n = 60)

Biochemical Parameter	Baseline (Mean ± SD)	Follow-up (Mean ± SD)	Observed Trend / Interpretation
Proteinuria (g/day) *	1.42 ± 0.58	1.12 ± 0.51	Reduction indicating improved glomerular integrity
Serum sodium (mmol/L)	137.6 ± 3.8	138.1 ± 3.5	Maintained within normal range
Serum potassium (mmol/L)	4.6 ± 0.5	4.5 ± 0.4	Stable, no hyperkalemia
C-reactive protein (mg/L) *	6.8 ± 2.4	5.3 ± 2.1	Decrease suggesting reduced inflammation
Oxidative stress marker**	Elevated	Moderately reduced	Downward trend
Overall biochemical stability	—	—	Maintained during therapy

*Available in a subset of patients with longitudinal data

**Includes documented oxidative stress or inflammatory indices where available

3.5 Predictors of Favorable Renal Outcomes

Treatment duration and baseline disease stage were the significant predictors of renal outcome stabilization identified by multivariable analysis. Individuals with more chronic kidney disease in the past showed better retention of estimated glomerular filtration rate in comparison to patients with advanced chronic kidney disease. Stable drug stimulus exposure was linked to the continued enhancement of biochemical tendencies. Age and gender were not found to show any independent relationship with variability in renal outcomes. Biochemical response magnitude was affected by comorbid burden, but it did not reduce therapeutic benefit. These predictors pointed out the significance of timely intervention and continued treatment in the treatment of chronic kidney diseases. The results of the analysis were in favor of customized nephroprotective interventions, which could be guided by biochemical studies, which confirms the translational application of the study results.

4. DISCUSSION

This retrospective pharmacobiochemical analysis has shown that the renoprotective pharmacotherapy was linked to renal functional stability and positive biochemical course in patients with chronic kidney disease. The studies indicated that changes in the decline of estimated glomerular filtration rate and stabilization of serum creatinine and urea indicated kidney preservation of remaining renal functions in normal clinical practice. Therapeutic benefit without signs of destabilization of metabolic state was also supported by secondary biochemical parameters, such as proteinuria and electrolyte balance. These results demonstrated the usefulness of pharmacologically induced nephroprotection beyond the aetiology of the disease, and represent real-world utility and not controlled trial utility. The lack of gender-related

differences was an indication of a similar response in biochemistry in both male and female patients. Altogether, the findings supported the contribution of the long-term pharmacological intervention to regulating the CKD advancement by quantifiable biochemical and functional renal outcomes.

The pharmacobiochemical stabilization that was observed was in accordance with mechanistic knowledge regarding renoprotective agents. SGLT2 inhibitors are shown to have renal hemodynamic adjustment, a decrease in intraglomerular pressure, and inhibition of oxidative stress, including biochemical stabilization in the populations with CKD [16]. Optimized pharmacological interventions to increase the efficacy of renin-angiotensin-aldosterone system blockade have been found to postpone the renal failure, as is in line with the maintained eGFR patterns in the current cohort [17]. Finerenone, as an antagonist of the mineralocorticoid receptor, is linked to better renal outcomes across glycaemic lines, which is consistent with the biochemical stability despite metabolic background [18]. Reductions in albuminuria and delaying eGFR in ACE inhibitors and ARBs are further demonstrated by systematic studies, which are consistent with the observation of renal function preservation in this study [19]. Also, the control of oxidative stress and fibrosis as a therapeutic outcome offers a mechanistic background to the reported biochemical advances [20]. Complementary renoprotective activity between SGLT2 inhibitors and non-steroidal MRAs has been shown to have complementary activity in promoting the pharmacological relevance of combination or stage-specific therapy [21]. Inhibitors of the renin-angiotensin system have also been found to display superior renal outcomes in advanced CKD using RAAS-based interventions, a finding that has been supported by those of the current study [22].

There are a few drawbacks that should be mentioned. The retrospective design restricted the ability to make a causal inference and relied on the completeness and accuracy of medical records. Biochemical parameters were limited to the laboratory values that were routinely documented, which will not allow a consistent evaluation of newer or molecular biomarkers for all patients. Heterogeneity in the treatment duration, dose, and combination therapy reflected real-world practice but did not allow complete control of this heterogeneity. The sample size was relatively small, which limited subgroup outcomes to CKD stages and pharmacological classes. Also, long-term renal outcomes like the development of end-stage kidney disease were not consistently reported, which restricted the extrapolation of outcomes. In spite of these limitations, the methodology delivered clinically relevant information that is representative of everyday nephrology care. The results supported the clinical importance of pharmacobiochemical monitoring in the management of the renoprotective therapy of chronic kidney disease. The significance of early use and prolonged use of nephroprotective agents was supported by stabilization of the renal function parameters of patients under routine care. Clinically, the biochemical trends provided pragmatic indicators of efficacy in therapy and optimality of treatment. In the case of research, the data justified the further incorporation of retrospective real-world evidence with prospective validation research to narrow down on patient-specific treatment strategies. Mechanism-based studies that include the use of molecular biomarkers, indices of fibrosis, and extended follow-up would promote a better comprehension and prediction of outcomes. All this research brought valuable observational information to the field of pharmacological nephroprotection in the paradigms of modern CKD management, highlighted by the articles of the nephrology-specific journals.

5. CONCLUSION

This post factum pharmacobiochemical assessment showed that renoprotective pharmacotherapy had a relation to renal function stabilization and positive biochemical progress in chronic renal disease patients. Evaluation of routinely followed parameters, such as serum creatinine, estimated glomerular filtration rate, urea, and proteinuria, revealed the reduction of the disease progression under the conditions of real-life clinical conditions. The results demonstrated uniform biochemical reactions by both genders to indicate the wide range of applicability of renoprotective measures in normal nephrology practice. Preservation of residual renal function was linked to pharmacological exposure as opposed to reversal of established damage, regardless of the need to have sustained therapy and follow-ups. Together, the findings supported the clinical significance of the combination of pharmacological management with biochemical analysis in the management of chronic kidney disease. The next line of research will involve future validation of the findings in bigger and more diverse populations to facilitate causal inference. Mechanistic pathways of pharmacological nephroprotection would also be further explained by the incorporation of molecular biomarkers, inflammatory indices, and fibrosis markers. Long-term studies that may assess the transition to end-stage kidney disease, dialysis commencement, and mortality outcomes would be more clinically applicable. Moreover, comparative effectiveness studies in each of the classes of renoprotective drugs and using combination therapies could guide personalized treatment plans. A combination of real-world data with precision medicine services can be used to streamline the therapeutic decision-making process and enhance long-term renal treatment outcomes in the management of chronic kidney disease.

REFERENCE

1. Heerspink HJ, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JF, McMurray JJ, Lindberg M, Rossing P, Sjöström CD. Dapagliflozin in patients with chronic kidney disease. *New England Journal of Medicine*. 2020 Oct 8;383(15):1436-46.
2. Wheeler DC, Stefánsson BV, Batiushin M, Bilchenko O, Cherney DZ, Chertow GM, Douthat W, Dwyer JP, Escudero E, Pecoits-Filho R, Furuland H. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. *Nephrology Dialysis Transplantation*. 2020 Oct;35(10):1700-11.
3. McMurray JJ, Wheeler DC, Stefánsson BV, Jongs N, Postmus D, Correa-Rotter R, Chertow GM, Greene T, Held C, Hou FF, Mann JF. Effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease. *Circulation*. 2021 Feb 2;143(5):438-48.

4. Yu MK, Vart P, Jongs N, Correa-Rotter R, Rossing P, McMurray JJ, Hou FF, Douthat W, Khullar D, Langkilde AM, Wheeler DC. Effects of dapagliflozin in chronic kidney disease across the spectrum of age and by sex. *Journal of General Internal Medicine*. 2024 May;39(6):921-30.
5. Bakris GL, Ruilope LM, Anker SD, Filippatos G, Pitt B, Rossing P, Fried L, Roy-Chaudhury P, Sarafidis P, Ahlers C, Brinker M. A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes. *Kidney International*. 2023 Jan 1;103(1):196-206.
6. Sato A, Nishimoto M. Real-world use of finerenone in patients with chronic kidney disease and type 2 diabetes based on large-scale clinical studies: FIDELIO-DKD and FIGARO-DKD. *Hypertension Research*. 2025 Mar 25:1-0.
7. Marx N, Floege J. Dapagliflozin, advanced chronic kidney disease, and mortality: new insights from the DAPA-CKD trial. *European Heart Journal*. 2021 Apr 1;42(13):1228-30.
8. Alshahrani S. Renin-angiotensin-aldosterone pathway modulators in chronic kidney disease: a comparative review. *Front Pharmacol*. 2023; 14: 1101068 [Internet]. 2023
9. Mukoyama M, Kuwabara T. Role of renin-angiotensin system blockade in advanced CKD: to use or not to use?. *Hypertension Research*. 2022 Jun;45(6):1072-5.
10. Kale N, Dighe P. Review on SGLT2 Inhibitors. *Asian Journal of Pharmaceutical Research and Development*. 2023 Apr 30;11(2):98-106.
11. Bellos I, Marinaki S, Lagiou P, Benetou V. Comparative efficacy and safety of cardio-renalprotective pharmacological interventions in chronic kidney disease: an umbrella review of network meta-analyses and a multicriteria decision analysis. *Biomolecules*. 2024 Dec 31;15(1):39.
12. Bhandari S, Mehta S, Khawaja A, Cleland JG, Ives N, Cockwell P. Evaluation of the stopping angiotensin converting enzyme inhibitor compared to angiotensin receptor blocker (STOP ACEi trial) in advanced and progressive chronic kidney disease. *Kidney International*. 2024 Jan 1;105(1):200-8.
13. Zhao HJ, Li Y, Liu SM, Sun XG, Li M, Hao Y, Cui LQ, Wang AH. Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis. *Renal failure*. 2016 Jul 2;38(6):849-56.
14. Hoher B. Reno- and cardioprotective molecular mechanisms of 4 SGLT2 inhibitors beyond glycemic control-from 5 bedside to bench. 6.
15. Fioretto P, Pontremoli R. Expanding the therapy options for diabetic kidney disease. *Nature Reviews Nephrology*. 2022 Feb;18(2):78-9.
16. Pinto LH. Renoprotective Mechanisms of SGLT2 Inhibitors in Type 2 Diabetes Patients with Chronic Kidney Disease. *Renoprotective Mechanisms of SGLT2 Inhibitors in Type 2 Diabetes Patients with Chronic Kidney Disease*. 2022 May 18.
17. Lambers Heerspink HJ, De Borst MH, Bakker SJ, Navis GJ. Improving the efficacy of RAAS blockade in patients with chronic kidney disease. *Nature Reviews Nephrology*. 2013 Feb;9(2):112-21.
18. Rossing P, Burgess E, Agarwal R, Anker SD, Filippatos G, Pitt B, Ruilope LM, Gillard P, MacIsaac RJ, Wainstein J, Joseph A. Finerenone in patients with chronic kidney disease and type 2 diabetes according to baseline HbA1c and insulin use: an analysis from the FIDELIO-DKD study. *Diabetes Care*. 2022 Apr 1;45(4):e888-97.
19. Avula A, Johal LK, Ali F, Amir S, Yadav S, Murtuza M, Zia U, Janjua FF, Raza A, Lal K, Abid M. ACE Inhibitors and ARBs in Chronic Kidney Disease: A Systematic Review of Randomized Controlled Trials on Albuminuria Reduction, eGFR Decline, and Safety. *Cureus*. 2025 Oct 2;17(10).
20. Patera F, Gatticchi L, Cellini B, Chiasserini D, Reboldi G. Kidney fibrosis and oxidative stress: from molecular pathways to new pharmacological opportunities. *Biomolecules*. 2024 Jan 22;14(1):137.
21. Yang SQ, Zhao X, Zhang J, Liu H, Wang YH, Wang YG. Comparative efficacy and safety of SGLT2is and ns-MRAs in patients with diabetic kidney disease: a systematic review and network meta-analysis. *Frontiers in Endocrinology*. 2024 Jul 4;15:1429261.
22. Fu EL, Clase CM, Evans M, Lindholm B, Rotmans JJ, Dekker FW, van Diepen M, Carrero JJ. Comparative effectiveness of renin-angiotensin system inhibitors and calcium channel blockers in individuals with advanced CKD: a nationwide observational cohort study. *American Journal of Kidney Diseases*. 2021 May 1;77(5):719-29.